A retrospective analysis of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy for advanced or recurrent non ‐small cell lung cancer

ConclusionThere was no significant difference in ORR and OS between the two groups, and treatment discontinuation was more frequent in the combination group. A randomized controlled trial is needed to evaluate the addition of chemotherapy to pembrolizumab for first ‐line treatment in patients with PD‐L1 TPS ≥50%.

Source: Thoracic Cancer - March 12, 2021 Category: Cancer & Oncology Authors: Taisuke Isono, Naho Kagiyama, Shun Shibata, Hitomi Nakajima, Yuma Matsui, Kenji Takano, Takashi Nishida, Chiaki Hosoda, Eriko Kawate, Yoichi Kobayashi, Takashi Ishiguro, Yotaro Takaku, Kazuyoshi Kurashima, Tsutomu Yanagisawa, Noboru Takayana Tags: ORIGINAL ARTICLE Source Type: research